Amgen Inc. AMGN

NASDAQ · Healthcare · Drug Manufacturers - General

$435.64

Close on Fri, 20 Nov 2026 · market value $236B

What the price is betting on

Below its record

At $436, the price assumes revenue grows about 2.9% a year for five years, from $38.9B to about $43.9B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.

The price assumes2.9%
Analysts, next two years4.9%
Last 3 years12%

Revenue growth a year. The price figure comes from a reverse DCF at a 7.1% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than AMGN? Check up to 5 of your stocks at once, free, no account.

0$20B$40B$60B$38.9B'22'23'24'25Sep '26'26'27'28'29'30What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$432

Base

$483

Bull

$541

Today $436

  • Bear $432. Cash flow grows 3% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $483. Cash flow grows 5% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $541. Cash flow grows 7% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2026$39.2B$39.5B, on the path
  3. FY2027$40.3B$41.3B, on the path
  4. FY2028$41.5B$43.3B, on the path
  5. FY2029$42.6B$45.1B, on the path
  6. FY2030$43.9B$47.5B, on the path

Each year's revenue at 2.9% growth from $38.9B in the 12 months to September 2026.

At a glance

Healthcare · Drug Manufacturers - General · listed on NASDAQ

Revenue, FY2025
$36.7B
Growth, 3 years a year
12%
Cash margin
22%
Net debt
$45.5B
Shares, 3-year change
+0.2%
Dividend yield
2.2%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.